Novartis, CH0012005267

Novartis stock faces FDA review after nine Zolgensma tumor reports

Published on 11/11/2026 at 12:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The FDA says Zolgensma's benefits still outweigh potential risks as it considers regulatory action. Patients receiving the therapy should be monitored for tumors.

Safety Review Puts Focus on Gene Therapy

The FDA is assessing tumor risks linked to Zolgensma and the related Itvisma treatment.
Novartis said two cases showed vector DNA integration, while both patients remain under medical monitoring.
The FDA continues to weigh the benefits of both therapies above their potential risks for approved uses.

Novartis, CH0012005267, Illustration mit AI erstellt.

The U.S. Food and Drug Administration is investigating tumor reports linked to Novartis' Zolgensma gene therapy, according to a Nov. 6 safety communication cited by Becker's Hospital Review. The agency is evaluating whether further regulatory action is appropriate.

FDA Reviews Tumor Risk

Novartis has received nine reports of tumors in patients treated with Zolgensma since the therapy's first approval in 2019. Two cases showed evidence that the therapy's viral-vector DNA had integrated into patients' DNA, and both patients have received treatment and remain under medical monitoring.

The reports involve tumors in the central and peripheral nervous systems, spinal and paraspinal regions, and the kidney. Three cases involved the GLI1 oncogene. In two cases, the FDA said molecular analysis found vector DNA integrated into the genome near or within that gene; the mechanism behind GLI1 overexpression in the third case remains under investigation.

The FDA said the risk applies to Zolgensma and Itvisma because both products use the same vector and construct. No neoplasia cases have been reported after Itvisma to date. The agency continues to say that the overall benefits of both therapies outweigh their potential risks for approved uses, while it reviews current prescribing information and Novartis' long-term follow-up studies.

Stock Context for Investors

Novartis stock traded at 144.28 euros on Lang & Schwarz at 12:21 CET on Wednesday, November 11, 2026. The regulatory review adds a safety issue for investors to monitor alongside the company's broader pharmaceutical pipeline, but the FDA has not announced a product withdrawal or new prescribing restriction in the cited communication.